Prospective Phase III validation for EndoPredict – Read more

Prolaris Prostate Cancer Prognostic Test

Gain clarity in your prostate cancer treatment management

Prolaris® helps you understand your unique prostate cancer with a simple result that can guide the best treatment for you

Deeper insights

Clearer results

Confident choices

Understanding your prostate cancer diagnosis can be overwhelming

Determining the cancer’s behaviour influences the treatment plan. Over-treatment can lead to unnecessary side effects, while under-treatment can allow the cancer to progress.

Prolaris® has the answers you need

Prolaris® is the most comprehensive and accurate genomic test1,2 that empowers you and your doctor to make informed treatment decisions.

Deeper insights

Discover your long-term prognosis with Prolaris®, a genomic test that adds an extra layer of predictive power compared to PSA and Gleason score.1

Clearer results

Combines all the information about your tumour into one, easy-to-understand result that shows the best treatment approach for you.

Confident choices

Gain peace of mind and confidence in your chosen treatment, knowing that Prolaris® is shown to accurately predict long-term outcomes.1-13

For confidence now and in the future

PSA and Gleason scores used as prognostic factors are not accurate enough to tell you how your cancer will progress. Prolaris® measures the activity of cell cycle progression (CCP) genes to determine the behaviour of your prostate cancer now and in the future. Combined with PSA and Gleason score, Prolaris® provides a more comprehensive view of your prostate cancer.1,2

This is how it works

Get familiarized with Prolaris® and prepare for your appointment with your doctor – download our patient guide today.

1

Your doctor sends a sample from your biopsy tissue to measure the activity of CCP genes in your cancer.

2

The lab uses Prolaris®, which includes your individual cancer genetic profile to show the risk of your cancer returning within 10 years.

3

Once results are available in around 2 weeks, they are sent securely to your doctor’s office. Your doctor will help you understand the results and make an informed treatment decision together.

Take control of your prostate cancer

Prolaris® is proven to be accurate and safe in trials involving over 11,000 patients.1-19 It’s also proven to work for patients across all risk groups.

Deeper insights

Prolaris® is a breakthrough in prostate cancer genomic testing. It goes further than traditional tests by looking at the specific genes in your cancer.1,2,20 This provides a more comprehensive view of your prostate cancer, allowing for a truly personalized treatment plan.

Clearer results

Understanding the nature of your prostate cancer is crucial in deciding the right treatment path. Prolaris® provides this clarity by determining your cancer’s behavior. The test result shows the risk of your prostate cancer getting worse within 10 years, giving you and your doctor the confidence to choose the right treatment.

Confident choices

Knowledge is power, especially when it comes to your health.

Prolaris® empowers you with detailed insights about your prostate cancer, enabling you to take an active role in your treatment decisions.

Your doctor can help answer your questions on Prolaris® and guide you through the testing process. You can also browse informative articles, research papers, and guides to help you understand more about prostate cancer and the Prolaris® test.

References

  1. Cuzick, J., et al. “Prognostic Value of a Cell Cycle Progression Signature for Prostate Cancer Death in a Conservatively Managed Needle Biopsy Cohort.” British Journal of Cancer, vol. 106, no. 6, 2012, pp. 1095-1099.
  2. Tward, J. D., et al. “The Clinical Cell-Cycle Risk (CCR) Score Is Associated with Metastasis after Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy with Dose Escalated Radiation.” International Journal of Radiation Oncology, Biology, Physics, 2021. DOI: 10.1016/j.ijrobp.2021.09.034
  3. Cuzick, J., et al. “Prognostic Value of an RNA Expression Signature Derived from Cell Cycle Proliferation Genes in Patients with Prostate Cancer: A Retrospective Study.” Lancet Oncology, vol. 12, 2011, pp. 245-255. DOI: 10.1016/S1470-2045(10)70295-3
  4. Cuzick, J., et al. “Validation of an RNA Cell Cycle Progression Score for Predicting Death from Prostate Cancer in a Conservatively Managed Needle Biopsy Cohort.” British Journal of Cancer, vol. 113, no. 3, 2015, pp. 382-389.
  5. Cuzick, Jack M., et al. “Validation of the Cell Cycle Progression Score to Differentiate Indolent from Aggressive Prostate Cancer in Men Diagnosed through Transurethral Resection of the Prostate Biopsy.” Cancer Reports (Hoboken, N.J.), vol. 5, no. 8, 2022, e1535. DOI: 10.1002/cnr2.1535
  6. Swanson, G. P., et al. “Cell-Cycle Risk Score More Accurately Determines the Risk for Metastases and Death in Prostatectomy Patients Compared with Clinical Features Alone.” The Prostate, vol. 81, 2021, pp. 261-267. DOI: 10.1002/pros.24103
  7. Lin, D., et al. “Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer as Candidates for Active Surveillance.” Urologic Oncology, vol. 36, no. 6, 2018, pp. 310.e7-310.e13. DOI: 10.1016/j.urolonc.2018.03.011
  8. Tward, J., et al. “Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-Cycle Risk (CCR) Score Threshold for Prognosticating Benefit from Multimodality Therapy.” Clinical Genitourinary Cancer, vol. 19, no. 4, 2021, pp. 296-304.e3. DOI: 10.1016/j.clgc.2021.01.003
  9. Tward, J., et al. “The Clinical Cell-Cycle Risk (CCR) Score Is Associated with Metastasis after Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy with Dose-Escalated Radiation.” International Journal of Radiation Oncology, Biology, Physics, 2021. Epub ahead of print. PMID: 34610388.
  10. Canter, D. J., et al. “Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.” European Urology, vol. 75, no. 3, 2019, pp. 515-522. DOI: 10.1016/j.eururo.2018.10.028
  11. Canter, D. J., et al. “Analysis of the Prognostic Utility of the Cell Cycle Progression (CCP) Score Generated from Needle Biopsy in Men Treated with Definitive Therapy.” Prostate Cancer and Prostatic Diseases, vol. 23, no. 1, 2020, pp. 102-107. DOI: 10.1038/s41391-019-0159-9
  12. Kaul, S., et al. “Clinical Outcomes in Men with Prostate Cancer Who Selected Active Surveillance Using a Clinical Cell Cycle Risk Score.” Personalized Medicine, vol. 16, no. 6, 2019, pp. 491-499.
  13. Koch, M. O., et al. “Use of the Cell Cycle Progression (CCP) Score for Predicting Systemic Disease and Response to Radiation of Biochemical Recurrence.” Cancer Biomarkers, vol. 17, no. 1, 2016, pp. 83-88. DOI: 10.3233/CBM-160620
  14. Tosoian, J. J., et al. “Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with National Comprehensive Cancer Network Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.” BJU International, vol. 120, 2017, pp. 808-814. DOI: 10.1111/bju.13911
  15. Freedland, S. J., et al. “Prognostic Utility of Cell Cycle Progression Score in Men with Prostate Cancer after Primary External Beam Radiation Therapy.” International Journal of Radiation Oncology, Biology, Physics, vol. 86, no. 5, 2013, pp. 848-853. DOI: 10.1016/j.ijrobp.2013.04.043
  16. Cooperberg, M. R., et al. “Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.” European Urology, vol. 79, no. 1, 2021, pp. 141-149. DOI: 10.1016/j.eururo.2020.09.003
  17. Bishoff, J. T., et al. “Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy.” The Journal of Urology, vol. 192, no. 2, 2014, pp. 409-414. DOI: 10.1016/j.juro.2014.02.003
  18. Morris, D. S., et al. “Prognostic Capabilities and Clinical Utility of Cell Cycle Progression Testing, Prostate Imaging Reporting and Data System, Version 2, and Clinicopathologic Data in Management of Localized Prostate Cancer.” Urologic Oncology: Seminars and Original Investigations, vol. 39, no. 6, 2021, pp. 366.e19-366.e28. DOI: 10.1016/j.urolonc.2020.11.016
  19. Léon, P., et al. “Comparison of Cell Cycle Progression Score with Two Immunohistochemical Markers (PTEN and Ki-67) for Predicting Outcome in Prostate Cancer after Radical Prostatectomy.” World Journal of Urology, vol. 36, 2018, pp. 1495-1500. DOI: 10.1007/s00345-018-2290-y
  20. Hu, J. C., et al. “Clinical Utility of Gene Expression Classifiers in Men with Newly Diagnosed Prostate Cancer.” JCO Precision Oncology, 2018, pp. 1-15. DOI: 10.1200/po.18.00163